In addition, TLR4 and TLR9 deficiency significantly reduces liver injury and blocks the progression of liver inflammation to hepatic fibrosis and HCC in a hepatic deletion of transforming growth factor-β-activated kinase 1 (Tak1ΔHep) mouse model (38), indicating that TLR3-mediated apoptosis may be a promising therapeutic target in HCC treatment (69). Here, TLR3 is linked to hepatocellular carcinoma.